Lee Greenbury: Provalis
Sarbanes-Oxley is forcing pharma company Provalis to delist from Nasdaq just as its US business starts to take off. As Husnara Begum finds, the move is keeping its sole lawyer busy Medical diagnostics and pharmaceuticals group Provalis is planning to terminate its American depositary receipt (ADR) programme and delist from Nasdaq. The moves will allow the company […]